PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins.
- Advertising -
Complete report available at www.marketreportsonline.com/734491.html.
This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment.
- Advertising -
PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.
PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer.
PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.
The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts.
However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.
The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S.
and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc.
are being profiled along with their key financials and strategies for growth.
Few Points from List of Charts:
Role of PARP
PARP Inhibitor Mechanism
Global PARP Inhibitor Market Forecast by Value (2017-2025)
Global PARP Inhibitor Market Forecast by Cancer Type (2017-2025)
Global PARP Inhibitor Market Share Forecast by Cancer Type (2020/2025)
Global PARP Inhibitor Market by Drug Type (2017)
Global Lynparza Market Forecast by Value (2017-2025)
Global Lynparza Market Forecast by Cancer Type (2017-2025)
Global Lynparza Market Forecast by Region (2017)
Global Rubraca Market Forecast by Value (2017-2025)
Global Rubraca Market Forecast by Cancer Type (2017-2025)
Global Rubraca Ovarian Market Forecast by Line Therapy (2017-2025)
Global Zejula Market Forecast by Value (2017-2025)
Global Zejula Market Forecast by Cancer Type (2017-2025)
Global Zejula Ovarian Market Forecast by Line Therapy (2017-2025)
The U.S. Ovarian Cancer Incidence Forecast (2017-2025)
Category: Market Research Publishers and RetailersCompany about: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
For more information: